We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.23B
AUM Growth
+$298M
(+4.3%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
1,100
New
151
Increased
415
Reduced
333
Closed
164
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.6M |
| 2 |
Autodesk
ADSK
|
+$38.8M |
| 3 |
Intuit
INTU
|
+$37.1M |
| 4 |
Ecolab
ECL
|
+$35.6M |
| 5 |
Coca-Cola
KO
|
+$35.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$51.9M |
| 2 |
EOG Resources
EOG
|
+$33.8M |
| 3 |
DATA
Tableau Software, Inc.
DATA
|
+$32M |
| 4 |
Microsoft
MSFT
|
+$29.8M |
| 5 |
Ford
F
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.67% |
| 2 | Financials | 17.68% |
| 3 | Consumer Discretionary | 13.74% |
| 4 | Industrials | 11.53% |
| 5 | Healthcare | 11.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Aspen Aerogels
ASPN
$387M
| $144K | ﹤0.01% |
20,251
-14,886
| -42% | -$67.6K |
|
902
Arcus Biosciences
RCUS
$3.57B
| $144K | ﹤0.01% |
+18,076
| New | +$181K |
|
|
RVLP
903
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $142K | ﹤0.01% |
+37,299
| New | +$124K |
|
904
Nature's Sunshine
NATR
$359M
| $140K | ﹤0.01% |
15,056
-5,342
| -26% | -$50K |
|
|
USAK
905
DELISTED
USA Truck Inc
USAK
| $139K | ﹤0.01% |
13,791
-89,309
| -87% | -$1.18M |
|
906
Lee Enterprises
LEE
$166M
| $131K | ﹤0.01% |
5,854
-590
| -9% | -$16.2K |
|
907
Vitamin Cottage Natural Grocers
NGVC
$691M
| $129K | ﹤0.01% |
+12,805
| New | +$147K |
|
908
Kodiak Sciences
KOD
$2.59B
| $122K | ﹤0.01% |
+10,400
| New | +$92.5K |
|
909
Universal Technical Institute
UTI
$2.08B
| $120K | ﹤0.01% |
34,925
| – | – |
|
|
SCPH
910
DELISTED
scPharmaceuticals
SCPH
| $118K | ﹤0.01% |
36,921
+13,225
| +56% | +$43.3K |
|
911
Cogent Biosciences
COGT
$6.79B
| $117K | ﹤0.01% |
11,194
-16,075
| -59% | -$214K |
|
|
ALSK
912
DELISTED
Alaska Communications Systems
ALSK
| $117K | ﹤0.01% |
68,573
-21,700
| -24% | -$37.9K |
|
913
Tilly's
TLYS
$115M
| $115K | ﹤0.01% |
+15,052
| New | +$152K |
|
|
PMBC
914
DELISTED
Pacific Mercantile Bancorp
PMBC
| $109K | ﹤0.01% |
13,218
-15,170
| -53% | -$121K |
|
915
LSI Industries
LYTS
$853M
| $102K | ﹤0.01% |
27,885
+3,300
| +13% | +$11.3K |
|
916
Ardelyx
ARDX
$1.24B
| $100K | ﹤0.01% |
37,209
-40,790
| -52% | -$123K |
|
917
SandRidge Energy
SD
$510M
| $98K | ﹤0.01% |
14,200
| – | – |
|
|
WOW
918
DELISTED
WideOpenWest
WOW
| $98K | ﹤0.01% |
13,478
-338,528
| -96% | -$2.76M |
|
|
ACHN
919
DELISTED
Achillion Pharmaceuticals
ACHN
| $98K | ﹤0.01% |
36,500
-280,595
| -88% | -$829K |
|
|
JAG
920
DELISTED
Jagged Peak Energy Inc.
JAG
| $97K | ﹤0.01% |
+11,682
| New | +$113K |
|
|
RNWK
921
DELISTED
RealNetworks Inc
RNWK
| $94K | ﹤0.01% |
49,620
-15,600
| -24% | -$35.5K |
|
|
ALPN
922
DELISTED
Alpine Immune Sciences Inc
ALPN
| $90K | ﹤0.01% |
+21,274
| New | +$123K |
|
923
Amtech Systems
ASYS
$278M
| $85K | ﹤0.01% |
+15,428
| New | +$94.1K |
|
|
LBY
924
DELISTED
Libbey, Inc.
LBY
| $81K | ﹤0.01% |
+43,588
| New | +$101K |
|
|
NVTR
925
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $65K | ﹤0.01% |
+19,445
| New | +$123K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2019 Portfolio in Review
As of Q2 2019, Jacobs Levy Equity Management held 1,100 positions worth $7.23B, up 4.3% from $6.93B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Jacobs Levy Equity Management's Q2 2019 filing shows 151 new, 415 increased, 333 reduced and 164 closed positions. Its largest new stake was Biogen: 175,817 shares worth $41.1M. The largest sale was Allergan plc, an estimated $51.9M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2019 buy was Biogen: 175,817 shares worth $41.1M.
- Jacobs Levy Equity Management added most to Ecolab in Q2 2019, an estimated $35.6M increase.
- Jacobs Levy Equity Management's biggest Q2 2019 reduction was EOG Resources, cutting an estimated $33.8M.
- Jacobs Levy Equity Management fully exited Allergan plc in Q2 2019, selling an estimated $51.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 15% of its $7.23B portfolio in Q2 2019.
- Jacobs Levy Equity Management opened 151 new positions and closed 164 in Q2 2019.
- Jacobs Levy Equity Management's portfolio value rose 4.3% quarter-over-quarter to $7.23B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.